How Novo Nordisk's weight loss pill is drawing in new patients for obesity treatment

Novo Nordisk's latest GLP-1 weight loss drug comes in pill form. Its ease of access has drawn in new obesity patients who may have opted against its injectable predecessor. After the drug's first few months on the market, it faces fresh competition following FDA approval of Eli Lilly's rival oral weight loss pill. CNBC's Annika Kim Constantino breaks down how this medicine is impacting the pharmaceutical industry.